Funding for this research was provided by:
Ministry of Health, Labour and Welfare (19H03700, 17K09990)
Received: 10 August 2020
Accepted: 25 December 2020
First Online: 1 February 2021
Ethics approval and consent to participate
: The study was approved by the Ethics Committee of YCU (A191100002). This survey is based on the application of the opt-out strategy in accordance with Japan MHLW Epidemiological Research Ethics Guidelines.
: Not applicable.
: Y. Kirino: Amgen (speaking and consultation fees); M. Takeno: Amgen (advisor for the clinical trial of Apremilast); and S. Nagaoka: Chugai, Bristol-Myers Squibb, Gilead (consultation fees).